FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320121320> ?p ?o ?g. }

• W2320121320 endingPage "1291" @default.
• W2320121320 startingPage "1286" @default.
• W2320121320 abstract "BackgroundRET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, the benefits of pemetrexed-based treatments in patients with RET-rearranged lung cancers relative to other genomic subsets have not previously been explored.Patients and methodsA retrospective review of patients with pathologically confirmed stage IIIB/IV lung adenocarcinomas and evidence of a RET, ROS1, or ALK rearrangement, or a KRAS mutation was conducted. Patients were eligible if they received treatment with pemetrexed alone or in combination. The primary outcome of progression-free survival (PFS), and secondary outcomes of overall response rate (ORR, RECIST v1.1), time to progression (TTP), and time to treatment discontinuation were compared between RET-rearranged and groups of ROS1-rearranged, ALK-rearranged, and KRAS-mutant lung cancers.ResultsWe evaluated 104 patients. Patients with RET-rearranged lung cancers (n = 18) had a median PFS of 19 months [95% confidence interval (CI) 12–not reached (NR)] that was comparable with patients with ROS1- (23 months, 95% CI 14–NR, n = 10) and ALK-rearranged (19 months, 95% CI 15–36, n = 36) lung cancers, and significantly improved compared with patients with KRAS-mutant lung cancers (6 months, 95% CI 5–9, P < 0.001, n = 40). ORR (45%), median TTP (20 months, 95% CI 17–NR), and median time to treatment discontinuation (21 months, 95% CI 6–NR) in patients with RET-rearranged lung cancers were not significantly different compared with patients with ALK- and ROS1-rearranged lung cancers, and improved compared with patients with KRAS-mutant lung cancers.ConclusionDurable benefits with pemetrexed-based therapies in RET-rearranged lung cancers are comparable with ALK- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET-rearranged lung cancers, pemetrexed-containing regimens should be considered." @default.
• W2320121320 created "2016-06-24" @default.
• W2320121320 creator A5019970204 @default.
• W2320121320 creator A5023061236 @default.
• W2320121320 creator A5024203424 @default.
• W2320121320 creator A5029805571 @default.
• W2320121320 creator A5030479930 @default.
• W2320121320 creator A5037884911 @default.
• W2320121320 creator A5039791495 @default.
• W2320121320 creator A5040823898 @default.
• W2320121320 creator A5045981082 @default.
• W2320121320 creator A5046345178 @default.
• W2320121320 creator A5046460245 @default.
• W2320121320 creator A5047449409 @default.
• W2320121320 creator A5060393514 @default.
• W2320121320 creator A5063199354 @default.
• W2320121320 creator A5078938585 @default.
• W2320121320 creator A5091615631 @default.
• W2320121320 date "2016-07-01" @default.
• W2320121320 modified "2023-10-09" @default.
• W2320121320 title "Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers" @default.
• W2320121320 cites W1982488143 @default.
• W2320121320 cites W2019539885 @default.
• W2320121320 cites W2019607817 @default.
• W2320121320 cites W2049553585 @default.
• W2320121320 cites W2050249255 @default.
• W2320121320 cites W2065799563 @default.
• W2320121320 cites W2099530756 @default.
• W2320121320 cites W2104347254 @default.
• W2320121320 cites W2119317963 @default.
• W2320121320 cites W2125665528 @default.
• W2320121320 cites W2130488043 @default.
• W2320121320 cites W2132578211 @default.
• W2320121320 cites W2135192471 @default.
• W2320121320 cites W2146448515 @default.
• W2320121320 cites W2156353875 @default.
• W2320121320 cites W2158638287 @default.
• W2320121320 cites W2168404690 @default.
• W2320121320 cites W223909586 @default.
• W2320121320 cites W2560367415 @default.
• W2320121320 cites W2572174216 @default.
• W2320121320 doi "https://doi.org/10.1093/annonc/mdw163" @default.
• W2320121320 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4922319" @default.
• W2320121320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27056998" @default.
• W2320121320 hasPublicationYear "2016" @default.
• W2320121320 type Work @default.
• W2320121320 sameAs 2320121320 @default.
• W2320121320 citedByCount "84" @default.
• W2320121320 countsByYear W23201213202016 @default.
• W2320121320 countsByYear W23201213202017 @default.
• W2320121320 countsByYear W23201213202018 @default.
• W2320121320 countsByYear W23201213202019 @default.
• W2320121320 countsByYear W23201213202020 @default.
• W2320121320 countsByYear W23201213202021 @default.
• W2320121320 countsByYear W23201213202022 @default.
• W2320121320 countsByYear W23201213202023 @default.
• W2320121320 crossrefType "journal-article" @default.
• W2320121320 hasAuthorship W2320121320A5019970204 @default.
• W2320121320 hasAuthorship W2320121320A5023061236 @default.
• W2320121320 hasAuthorship W2320121320A5024203424 @default.
• W2320121320 hasAuthorship W2320121320A5029805571 @default.
• W2320121320 hasAuthorship W2320121320A5030479930 @default.
• W2320121320 hasAuthorship W2320121320A5037884911 @default.
• W2320121320 hasAuthorship W2320121320A5039791495 @default.
• W2320121320 hasAuthorship W2320121320A5040823898 @default.
• W2320121320 hasAuthorship W2320121320A5045981082 @default.
• W2320121320 hasAuthorship W2320121320A5046345178 @default.
• W2320121320 hasAuthorship W2320121320A5046460245 @default.
• W2320121320 hasAuthorship W2320121320A5047449409 @default.
• W2320121320 hasAuthorship W2320121320A5060393514 @default.
• W2320121320 hasAuthorship W2320121320A5063199354 @default.
• W2320121320 hasAuthorship W2320121320A5078938585 @default.
• W2320121320 hasAuthorship W2320121320A5091615631 @default.
• W2320121320 hasBestOaLocation W23201213201 @default.
• W2320121320 hasConcept C104317684 @default.
• W2320121320 hasConcept C117643217 @default.
• W2320121320 hasConcept C121608353 @default.
• W2320121320 hasConcept C126322002 @default.
• W2320121320 hasConcept C143998085 @default.
• W2320121320 hasConcept C167135981 @default.
• W2320121320 hasConcept C185592680 @default.
• W2320121320 hasConcept C2775999482 @default.
• W2320121320 hasConcept C2776232967 @default.
• W2320121320 hasConcept C2776256026 @default.
• W2320121320 hasConcept C2776694085 @default.
• W2320121320 hasConcept C2777240266 @default.
• W2320121320 hasConcept C2777714996 @default.
• W2320121320 hasConcept C2778239845 @default.
• W2320121320 hasConcept C2778715236 @default.
• W2320121320 hasConcept C2779422266 @default.
• W2320121320 hasConcept C2781182431 @default.
• W2320121320 hasConcept C2781187634 @default.
• W2320121320 hasConcept C2992511266 @default.
• W2320121320 hasConcept C526805850 @default.
• W2320121320 hasConcept C55493867 @default.
• W2320121320 hasConcept C71924100 @default.
• W2320121320 hasConcept C90924648 @default.
• W2320121320 hasConceptScore W2320121320C104317684 @default.

• next